拉米夫定和普通干扰素初始联合治愈HBeAg阳性CHB患者1例

A case of CHB patients with HBeAg positive who was treated with initial combination of lamivudine and interferon

实现HBsAg转阴和转化是CHB治疗的理想终点。本文报告1例HBeAg阳性CHB患者初始联合拉米夫定和普通干扰素治疗,治疗48周后实现HBsAg转阴,在继续联合抗病毒治疗的基础上接种乙肝疫苗(0个月、1个月、6个月),64周时HBsAb达50mIU/ml,72周时达150mIU/ml,判定为临床治愈,停止抗病毒治疗。提示科学合理联合抗病毒治疗,必要时加用乙肝疫苗和免疫增强剂,可能使CHB患者达到临床治愈。

Realization of HBsAg negative conversion and transformation is the ideal endpoint of CHBtherapy. We reported a case of CHB patients with HBeAg positive who was given combination treatment oflamivudine （LAM） and interferon （IFN） for 48 weeks, and HBsAg conversed to be negative. On the basis ofanti-viral treatment, the patients were inoculated with hepatitis B vaccine （0 month, 1 month and 6 month）.The level of HBsAb was 50 mIU/ml at 64 week and 150 mIU/ml at 72 week. The patients get clinical cureand discontinued antiretroviral treatment. Among the different possibilities contemplated, combined treatmentis effective in HBV infection. The effectiveness of combined treatment should be researched with hepatitis Bvaccine or mmunopotentiator, as occasion requires.